Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species
PURPOSE: E6201 is a natural product-inspired novel inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEK1) and other kinases and is currently under development as an anticancer (parenteral administration) and antipsoriasis agent (topical application). In vitro and in vivo preclinical studies were performed to characterize the pharmacokinetics of E6201. Allometric scaling was applied to predict human pharmacokinetics of E6201.
METHODS: In vitro metabolism studies for CYP induction and CYP inhibition were conducted using human hepatocytes and microsomes, respectively. Metabolic stability using microsomes and protein-binding studies using pooled plasma were performed for mice, rats, dogs, and human. Pharmacokinetics of E6201 and its isomeric metabolite, ER-813010, in mice, rats, and dogs was determined following single IV administration of E6201 at three dose levels. Bioanalysis was performed using LC/MS/MS. Pharmacokinetic parameters were determined using non-compartmental analysis, and allometric scaling with a two-compartment model was used to predict E6201 pharmacokinetics in humans.
RESULTS: E6201 showed high plasma protein binding (>95%), and metabolic stability half-life ranged from 36 to 89 min across species. In vitro CYP inhibition (CYP1A2, 2C9, 2C19, 2D6, 2E1, and 3A) and CYP induction (CYP1A, 3A, 2C9, and 2C19) suggested no inhibitory or induction effect on the tested human CYPs up to 10 μM of E6201. Pharmacokinetics of E6201 in mice, rats, and dogs was characterized by mean clearance ranging from 3.45 to 10.92 L/h/kg, distribution volume ranging from 0.63 to 13.09 L/kg, and elimination half-life ranging from 0.4 to 1.6 h. ER-813010 was detected in all species with metabolite to parent exposure ratio (AUC(R)) ranging from 3.1 to 33.4% and exhibited fast elimination (<3 h). The allometry predicted high clearance and large volume of distribution of E6201 in humans and was in general in good agreement with the observed first human subject pharmacokinetics.
CONCLUSIONS: E6201 exhibited high clearance, high to moderate distribution, and fast elimination in preclinical species. In vitro results suggested that E6201 has low risk of drug-drug interactions due to CYP inhibition and induction in humans. In the first-in-man study, E6201 exhibited high clearance, which was well predicted by allometric scaling.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Cancer chemotherapy and pharmacology - 69(2012), 1 vom: 21. Jan., Seite 229-37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Vipul [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.02.2012 Date Revised 20.11.2014 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00280-011-1687-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM209408022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM209408022 | ||
| 003 | DE-627 | ||
| 005 | 20231224005729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00280-011-1687-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0698.xml |
| 035 | |a (DE-627)NLM209408022 | ||
| 035 | |a (NLM)21698359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Vipul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.02.2012 | ||
| 500 | |a Date Revised 20.11.2014 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: E6201 is a natural product-inspired novel inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEK1) and other kinases and is currently under development as an anticancer (parenteral administration) and antipsoriasis agent (topical application). In vitro and in vivo preclinical studies were performed to characterize the pharmacokinetics of E6201. Allometric scaling was applied to predict human pharmacokinetics of E6201 | ||
| 520 | |a METHODS: In vitro metabolism studies for CYP induction and CYP inhibition were conducted using human hepatocytes and microsomes, respectively. Metabolic stability using microsomes and protein-binding studies using pooled plasma were performed for mice, rats, dogs, and human. Pharmacokinetics of E6201 and its isomeric metabolite, ER-813010, in mice, rats, and dogs was determined following single IV administration of E6201 at three dose levels. Bioanalysis was performed using LC/MS/MS. Pharmacokinetic parameters were determined using non-compartmental analysis, and allometric scaling with a two-compartment model was used to predict E6201 pharmacokinetics in humans | ||
| 520 | |a RESULTS: E6201 showed high plasma protein binding (>95%), and metabolic stability half-life ranged from 36 to 89 min across species. In vitro CYP inhibition (CYP1A2, 2C9, 2C19, 2D6, 2E1, and 3A) and CYP induction (CYP1A, 3A, 2C9, and 2C19) suggested no inhibitory or induction effect on the tested human CYPs up to 10 μM of E6201. Pharmacokinetics of E6201 in mice, rats, and dogs was characterized by mean clearance ranging from 3.45 to 10.92 L/h/kg, distribution volume ranging from 0.63 to 13.09 L/kg, and elimination half-life ranging from 0.4 to 1.6 h. ER-813010 was detected in all species with metabolite to parent exposure ratio (AUC(R)) ranging from 3.1 to 33.4% and exhibited fast elimination (<3 h). The allometry predicted high clearance and large volume of distribution of E6201 in humans and was in general in good agreement with the observed first human subject pharmacokinetics | ||
| 520 | |a CONCLUSIONS: E6201 exhibited high clearance, high to moderate distribution, and fast elimination in preclinical species. In vitro results suggested that E6201 has low risk of drug-drug interactions due to CYP inhibition and induction in humans. In the first-in-man study, E6201 exhibited high clearance, which was well predicted by allometric scaling | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a ER 813010 |2 NLM | |
| 650 | 7 | |a Lactones |2 NLM | |
| 650 | 7 | |a MAP Kinase Kinase 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.12.2 |2 NLM | |
| 700 | 1 | |a Schuck, Edgar L |e verfasserin |4 aut | |
| 700 | 1 | |a Pelletier, Robert D |e verfasserin |4 aut | |
| 700 | 1 | |a Farah, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Condon, Krista B |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Rowbottom, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a King, Belinda M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhi-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Saxton, Philip L |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Y Nancy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d 1990 |g 69(2012), 1 vom: 21. Jan., Seite 229-37 |w (DE-627)NLM00036438X |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2012 |g number:1 |g day:21 |g month:01 |g pages:229-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00280-011-1687-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2012 |e 1 |b 21 |c 01 |h 229-37 | ||